- Home
- INVH vs BBIO Comparison
INVH vs BBIO Comparison
Compare INVH & BBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | INVH | BBIO |
|---|---|---|
| Founded | 2012 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.2B | 15.9B |
| IPO Year | 2016 | 2019 |
Fundamental Metrics
Financial Performance| Metric | INVH | BBIO |
|---|---|---|
| Price | $30.29 | $79.80 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 18 | 25 |
| Target Price | $32.50 | ★ $86.33 |
| AVG Volume (30 Days) | ★ 3.9M | 2.0M |
| Earning Date | 04-29-2026 | 05-12-2026 |
| Dividend Yield | ★ 4.28% | N/A |
| EPS Growth | ★ 29.73 | N/A |
| EPS | ★ 0.63 | N/A |
| Revenue | ★ $2,729,296,000.00 | $502,076,000.00 |
| Revenue This Year | $2.92 | $89.45 |
| Revenue Next Year | $2.43 | $73.78 |
| P/E Ratio | $48.09 | ★ N/A |
| Revenue Growth | 4.21 | ★ 126.26 |
| 52 Week Low | $24.25 | $46.81 |
| 52 Week High | $31.38 | $93.42 |
Technical Indicators
Market Signals| Indicator | INVH | BBIO |
|---|---|---|
| Relative Strength Index (RSI) | 54.91 | 45.74 |
| Support Level | $29.32 | $78.90 |
| Resistance Level | $30.78 | $85.34 |
| Average True Range (ATR) | 0.51 | 2.89 |
| MACD | -0.01 | -0.63 |
| Stochastic Oscillator | 60.84 | 9.96 |
Price Performance
Historical ComparisonAbout INVH Invitation Homes Inc.
Invitation Homes owns a portfolio of over 85,000 single-family rental homes. The company focuses on owning homes in the starter and move-up segments of the housing market with an average sale price around $350,000 and generally less than 1,800 square feet. The portfolio is spread across 17 target markets that feature high employment and household formation growth with over 70% of the portfolio in the Western US and Florida; 15 of the 17 markets featuring average rents lower than homeownership costs.
About BBIO BridgeBio Pharma Inc.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.